Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer

Esther H. Lips(The Netherlands Cancer Institute), Tapsi Kumar(The University of Texas MD Anderson Cancer Center), Anargyros Megalios(King's College London), Lindy L. Visser(The Netherlands Cancer Institute), Michael Sheinman(The Netherlands Cancer Institute), Angelo Fortunato(Biocom), Vandna Shah(King's College London), Marlous Hoogstraat(The Netherlands Cancer Institute), Emi Sei(The University of Texas MD Anderson Cancer Center), Diego Mallo(Biocom), Maria Roman-Escorza(King's College London), Ahmed A. Ahmed(King's College London), Mingchu Xu(The University of Texas MD Anderson Cancer Center), Alexandra W. van den Belt‐Dusebout(The Netherlands Cancer Institute), Wim Brugman(The Netherlands Cancer Institute), Tod D. Casasent(The University of Texas MD Anderson Cancer Center), Karen Clements(Public Health England), Helen Davies(University of Cambridge), Liping Fu(The Netherlands Cancer Institute), Anita Grigoriadis(King's College London), Timothy Hardman(Duke University), Lorraine King(Duke University), Marielle Krete(The Netherlands Cancer Institute), Petra Kristel(The Netherlands Cancer Institute), Michiel de Maaker(The Netherlands Cancer Institute), Carlo C. Maley(Biocom), Jeffrey R. Marks(Duke University), Brian A. Menegaz(Baylor College of Medicine), Lennart Mulder(The Netherlands Cancer Institute), Frank Nieboer(The Netherlands Cancer Institute), Salpie Nowinski(King's College London), Sarah E. Pinder(King's College London), Jelmar Quist(King's College London), Carolina Salinas-Souza(King's College London), Michael Schaapveld(The Netherlands Cancer Institute), Marjanka K. Schmidt(The Netherlands Cancer Institute), Abeer M. Shaaban(Queen Elizabeth Hospital Birmingham), Rana Shami(King's College London), Mathini Sridharan(King's College London), John H. Zhang(The University of Texas MD Anderson Cancer Center), Hilary Stobart(The Patients Association), Deborah Collyar(Orthopaedic Research of Virginia), Serena Nik‐Zainal(University of Cambridge), Lodewyk F.A. Wessels(The Netherlands Cancer Institute), E. Shelley Hwang(Duke University), Nicholas E. Navin(The University of Texas MD Anderson Cancer Center), P. Andrew Futreal(The University of Texas MD Anderson Cancer Center), P. Andrew Futreal(The University of Texas MD Anderson Cancer Center), E. Shelley Hwang(Duke University), Jos Jonkers(The Netherlands Cancer Institute), Jacco(The Netherlands Cancer Institute), Fariba Behbod(University of Kansas), Daniel Rea(Queen Elizabeth Hospital Birmingham), Proteeti Bhattacharjee(The Netherlands Cancer Institute), Donna Pinto, Ellen Verschuur(Borstkankervereniging Nederland), Marja van Oirsouw(Borstkankervereniging Nederland), Alastair M. Thompson(Baylor College of Medicine), Jelle Wesseling(Leiden University Medical Center), Elinor J. Sawyer(King's College London)
Nature Genetics
June 1, 2022
Cited by 89Open Access
Full Text

Abstract

Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and, despite treatment, a small fraction (5-10%) of DCIS patients develop subsequent invasive disease. A fundamental biologic question is whether the invasive disease arises from tumor cells in the initial DCIS or represents new unrelated disease. To address this question, we performed genomic analyses on the initial DCIS lesion and paired invasive recurrent tumors in 95 patients together with single-cell DNA sequencing in a subset of cases. Our data show that in 75% of cases the invasive recurrence was clonally related to the initial DCIS, suggesting that tumor cells were not eliminated during the initial treatment. Surprisingly, however, 18% were clonally unrelated to the DCIS, representing new independent lineages and 7% of cases were ambiguous. This knowledge is essential for accurate risk evaluation of DCIS, treatment de-escalation strategies and the identification of predictive biomarkers.


Related Papers

No related papers found

Powered by citation graph analysis